AC6 Stock Overview
Operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
AlzeCure Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.20 |
| 52 Week High | SEK 0.33 |
| 52 Week Low | SEK 0.042 |
| Beta | 0.30 |
| 1 Month Change | 18.84% |
| 3 Month Change | 378.97% |
| 1 Year Change | 36.67% |
| 3 Year Change | -4.21% |
| 5 Year Change | -58.25% |
| Change since IPO | -75.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| AC6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.5% | -6.6% | 0.8% |
| 1Y | 36.7% | -27.7% | 14.6% |
Return vs Industry: AC6 exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: AC6 exceeded the German Market which returned 14.6% over the past year.
Price Volatility
| AC6 volatility | |
|---|---|
| AC6 Average Weekly Movement | 33.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: AC6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AC6's weekly volatility has decreased from 39% to 34% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 11 | Martin Jönsson | www.alzecurepharma.se |
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications.
AlzeCure Pharma AB (publ) Fundamentals Summary
| AC6 fundamental statistics | |
|---|---|
| Market cap | €19.74m |
| Earnings (TTM) | -€3.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.1x
P/E RatioIs AC6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AC6 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 35.54m |
| Earnings | -SEK 35.54m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 26, 2025
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AC6 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/17 00:02 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AlzeCure Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonas Peciulis | Edison Investment Research |
| Fredrik Thor | Redeye |
| Felicia Rittemar | Vator Securities AB |